Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CX3CR1 | P49238 | 20/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8797 SCHEMBL29473543 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30914115 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL213194 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL212862 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL212398 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30914151 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL31643602 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23828002 | 0.99 | CX3CR1 (0.98) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23828005 | 0.99 | CX3CR1 (0.98) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30288320 | 0.99 | CX3CR1 (0.98) | CX3CR1CXCR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2025-07-17 | — | — | US | claimed |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-03-02 | — | — | US | claimed |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2021-06-24 | — | — | US | claimed |
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| US-12264165-B2 | Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2025-04-01 | — | — | US | disclosed |
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2024-08-13 | — | — | US | disclosed |
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-03-02 | — | — | US | disclosed |
| US-11542281-B2 | Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-01-03 | — | — | US | disclosed |
| US-11542281-B2 | Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-01-03 | — | — | US | disclosed |
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2022-05-24 | — | — | US | disclosed |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-11-04 | — | — | US | disclosed |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-09-23 | — | — | US | disclosed |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2021-06-24 | — | — | US | disclosed |
| CN-112218853-A | Process for the stereoselective preparation of chiral 2- [ (hetero) aralkylthio ] pyrimidines and products obtainable therefrom | 坎塞拉有限公司 | 2021-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, CYP2F1 | CX3CR1 3602/4885CXCR2 1814/4885ADORA1 367/4885 |
| US-12264165-B2 | Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom | CYP2B6, CYP2S1, CYP2D6 | CX3CR1 1795/4885CXCR2 430/4885ADORA1 170/4885 |
| US-11542281-B2 | Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom | CYP2S1, CYP2B6, CYP2F1 | CX3CR1 3602/4885CXCR2 1814/4885ADORA1 367/4885 |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, TYMS | CX3CR1 3509/4885CXCR2 1602/4885ADORA1 278/4885 |
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | CX3CR1, CXCR3, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 49/4885 |
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | CX3CR1, CCR5, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 54/4885 |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CCR5, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 54/4885 |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, TYMS | CX3CR1 3509/4885CXCR2 1602/4885ADORA1 278/4885 |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CXCR3, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 49/4885 |
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, CYP2F1 | CX3CR1 3602/4885CXCR2 1814/4885ADORA1 367/4885 |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | CYP2B6, CYP2S1, CYP2D6 | CX3CR1 1795/4885CXCR2 430/4885ADORA1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.